|
|
||||||||



* Complement Biology Group, Department of Medical Biochemistry, University of Wales College of Medicine, Heath Park, Cardiff, United Kingdom; and
Departments of Medicine and Immunology, University of Colorado Health Sciences Center, Denver, CO 80262
Complement receptor (CR) type 2 (CR2/CD21) is normally expressed
only during the immature and mature stages of B cell development. In
association with CD19, CR2 plays an important role in enhancing mature
B cell responses to foreign Ag. We used a murine V
2
promoter/V
24 enhancer minigene to develop transgenic mice that
initiate expression of human CR2 (hCR2) during the
CD43+CD25- late pro-B cell stage of
development. We found peripheral blood B cell numbers reduced by 60%
in mice expressing high levels of hCR2 and by 15% in mice with
intermediate receptor expression. Splenic B cell populations were
altered with an expansion of marginal zone cells, and basal serum IgG
levels as well as T-dependent immune responses were also significantly
decreased in transgenic mice. Mice expressing the highest levels of
hCR2 demonstrated in the bone marrow a slight increase in
B220intCD43+CD25- B cells in
association with a substantial decrease in immature and mature B cells,
indicative of a developmental block in the pro-B cell stage. These data
demonstrate that stage-specific expression of CR2 is necessary for
normal B cell development, as premature receptor expression
substantially alters this process. Alterations in B cell development
are most likely due to engagement of pre-B cell receptor-mediated or
other regulatory pathways by hCR2 in a CD19- and possibly C3
ligand-dependent manner.
This article has been cited by other articles:
![]() |
D. A. Kaminski and J. Stavnezer Antibody class switching differs among SJL, C57BL/6 and 129 mice Int. Immunol., April 1, 2007; 19(4): 545 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C. Hsiao, M. Lin, A. Tai, G. Chen, and B. T. Huber Cutting Edge: Epstein-Barr Virus Transactivates the HERV-K18 Superantigen by Docking to the Human Complement Receptor 2 (CD21) on Primary B Cells J. Immunol., August 15, 2006; 177(4): 2056 - 2060. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Birrell, L. Kulik, B. P. Morgan, V. M. Holers, and K. J. Marchbank B Cells from Mice Prematurely Expressing Human Complement Receptor Type 2 Are Unresponsive to T-Dependent Antigens J. Immunol., June 1, 2005; 174(11): 6974 - 6982. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lyubchenko, J. Dal Porto, J. C. Cambier, and V. M. Holers Coligation of the B Cell Receptor with Complement Receptor Type 2 (CR2/CD21) Using Its Natural Ligand C3dg: Activation without Engagement of an Inhibitory Signaling Pathway J. Immunol., March 15, 2005; 174(6): 3264 - 3272. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shoham, R. Rajapaksa, C. Boucheix, E. Rubinstein, J. C. Poe, T. F. Tedder, and S. Levy The Tetraspanin CD81 Regulates the Expression of CD19 During B Cell Development in a Postendoplasmic Reticulum Compartment J. Immunol., October 15, 2003; 171(8): 4062 - 4072. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |